Toulouse Chu
Welcome,         Profile    Billing    Logout  
 5 Trials 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BERTOZZI-SALAMON, Anne-Isabelle
SIOP-EP-II, NCT02265770 / 2013-002766-39: An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma

Recruiting
2/3
536
Europe, RoW
16 weeks of VEC + CDDP, Vincristine, Etoposide, Cyclophosphamide, Cisplatin, VEC + HD-MTX, Methotrexate, Chemotherapy + Valproate, Carboplatin, Valproate, Conformal radiotherapy, VEC, Chemotherapy, conformal radiotherapy +/- boost
Centre Leon Berard
Childhood Ependymoma
06/28
08/31
RETINO2018, NCT04681417 / 2019-005039-94: Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome

Recruiting
2/3
225
Europe
Melphalan or Melphalan + Topotecan, Alkeran, Topotecan Accord; Topotecan Hospira chemotherapy, etoposide, carboplatin and vincristine or local ophthalmological treatment without IV chemotherapy, etoposide, carboplatin and vincristine chemotherapy, Carboplatin administered on Day 1, platinum-based chemotherapy, Thermotherapy (local treatment), Thermotherapy after carboplatin administered on Day 1, Cryotherapy (local treatment), Iodine-125 plaques (local treatment), Intravitreal Melphalan chemotherapy injections (local treatment)
Institut Curie, Fondation Rothschild Paris
Retinoblastoma
01/35
01/36
RETINO2011, NCT02866136: Conservative Treatments of Retinoblastoma

Active, not recruiting
2
133
Europe
VP16, carboplatin, etoposide, vepesid, chemotherapy, Melphalan, Alkeran, chemotherapy, VP16, carboplatin, vincristin, etoposide, vepesid, leurocristine, Oncovin, chemotherapy, Carboplatin + laser day 1 (chemothermotherapy), Carbo-laser, platinum-based chemotherapy, Laser (local treatment), Laser diode, cryoapplication (local treatment), I125 radioactive plaques (local treatment), intravitreal Melphalan (local treatment)
Institut Curie, Fondation Rothschild Paris
Retinoblastoma, Children, Retinal Neoplasm
01/23
09/35
NCT02870907 / 2009-016448-38: Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)

Recruiting
2
185
Europe
Observation, Low risk group, Etoposide, Intermediate risk sub group 1, Vincristine, Intermediate risk sub group 2, Orbital irradiation, High risk group, Carboplatin, Cyclophosphamide, Thiotepa, Cytapheresis, Peripheral bood stem cell transplantation
Institut Curie
Retinoblastoma
03/30
09/30
CASTEX, Marie-Pierre
No trials found

Download Options